rct
    2021
    High Quality

    Midodrine for the prevention of vasovagal syncope: a randomized clinical trial

    Sheldon R, Faris P, Tang A, Ayala-Paredes F, Guzman J, Marquez M, Raj SR

    Published in Annals of Internal Medicine

    Key Findings

    Midodrine reduced the proportion of patients with at least one syncope over 12 months (28% vs 43% with placebo).

    Conclusions

    Midodrine is an effective drug option for recurrent vasovagal syncope in otherwise healthy patients.

    Limitations

    Modest sample; supine hypertension and adherence issues.

    Related Health Concerns

    Fainting

    Study Details

    Year:2021
    Sample Size:133
    Duration:52 weeks
    Quality Score:8/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.